Jones Financial Companies
NRSN icon

Jones Financial Companies’s NeuroSense Therapeutics NRSN Stock Holding History

Jones Financial Companies’s Portfolio NRSN Stock Details NRSN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$757 Hold
50
– – ﹤0.01% 4667
2026
Q1 		$731 Hold
50
– – ﹤0.01% 4427
2025
Q4 		$769 Hold
50
– – ﹤0.01% 4076
2025
Q3 		$1.24K Sell
50
-496
-91% -$14.5K ﹤0.01% 3843
2025
Q2 		$20.7K Buy
+546
New +$15.8K ﹤0.01% 2574

Other funds holding NRSN

UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
IAA
Independent Advisor Alliance Charlotte, North Carolina $4.27B AUM 45.92% 1-Year Est. Return
YAG
Yorkville Advisors Global Mountainside, New Jersey $86.2M AUM 41.28% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return
PNC Financial Services Group
PNC Financial Services Group Pittsburgh, Pennsylvania $202B AUM 37.79% 1-Year Est. Return
Pathstone Holdings
Pathstone Holdings Englewood, New Jersey $34.3B AUM 27.35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return
Creative Planning
Creative Planning Overland Park, Kansas $171B AUM 24.68% 1-Year Est. Return
HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return

Jones Financial Companies's NRSN Position: Q2 2026 in Review

Jones Financial Companies held its NeuroSense Therapeutics (NRSN) position steady in Q2 2026 at 50 shares worth $757. The position accounts for ﹤0.01% of the portfolio, ranked #4667.

Jones Financial Companies first reported a position in NRSN in Q2 2025 and has held it in 5 quarters since. The position peaked at $20.7K in Q2 2025. 12 funds tracked by Wall St. Rank hold NRSN as of Q2 2026.

  • Jones Financial Companies held 50 shares of NeuroSense Therapeutics worth $757 as of Q2 2026.
  • Jones Financial Companies left its NeuroSense Therapeutics share count unchanged in Q2 2026.
  • NeuroSense Therapeutics made up ﹤0.01% of Jones Financial Companies's portfolio in Q2 2026, its #4667 holding.
  • Jones Financial Companies first reported a position in NeuroSense Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • Jones Financial Companies's NeuroSense Therapeutics position peaked at $20.7K in Q2 2025.
  • 12 funds tracked by Wall St. Rank held NeuroSense Therapeutics as of Q2 2026.

Based on Jones Financial Companies's 13F filing for Q2 2026, filed 14 Aug 2026.